United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz Sells 10,000 Shares

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at $955,319.67. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.91, for a total transaction of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.62, for a total transaction of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $356.68, for a total transaction of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $361.95, for a total value of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00.
• On Monday, November 11th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The stock was sold at an average price of $407.32, for a total value of $6,109,800.00.
• On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00.
• On Friday, November 1st, Michael Benkowitz sold 14,700 shares of United Therapeutics stock. The shares were sold at an average price of $374.46, for a total transaction of $5,504,562.00.

United Therapeutics Trading Down 0.3 %

Shares of UTHR traded down $1.13 on Friday, reaching $351.17. 414,604 shares of the company's stock traded hands, compared to its average volume of 251,464. The stock's 50 day simple moving average is $365.03 and its two-hundred day simple moving average is $357.15. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The stock has a market cap of $15.68 billion, a PE ratio of 15.42, a PEG ratio of 0.95 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to analysts' expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the business posted $5.38 EPS. Analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on UTHR shares. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, January 16th. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. HC Wainwright boosted their target price on United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Finally, Argus raised their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $378.36.

Institutional Trading of United Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Toronto Dominion Bank raised its stake in shares of United Therapeutics by 0.8% in the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company's stock valued at $1,441,000 after buying an additional 37 shares during the period. MBB Public Markets I LLC purchased a new stake in United Therapeutics in the 2nd quarter worth about $1,079,000. The Manufacturers Life Insurance Company raised its stake in United Therapeutics by 37.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 98,783 shares of the biotechnology company's stock valued at $31,467,000 after acquiring an additional 26,840 shares during the period. Creative Planning lifted its holdings in United Therapeutics by 20.1% during the second quarter. Creative Planning now owns 3,613 shares of the biotechnology company's stock valued at $1,151,000 after purchasing an additional 605 shares during the last quarter. Finally, Capital Impact Advisors LLC bought a new position in United Therapeutics during the second quarter worth about $954,000. Institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.